Exscientia presents novel immuno-oncology biomarker for EXS-21546

Exscientia highlighted new data to identify patients that are more likely to respond to its A2A receptor antagonist, EXS-21546 as well as the relationship to potential impact of adenosine on PD-1 inhibitor response. The research identified a novel patient selection multi-gene transcript signature, the adenosine burden score ABS , that will be confirmed in the Company’s Phase 1/2 study, IGNITE-AI. The data are being presented at the ESMO Immuno-Oncology Annual Congress, being held December 7-9 in Geneva, Switzerland. In this study, researchers leveraged Exscientia’s translational oncology platform with transcriptomics, to develop and begin pre-clinical biological confirmation of the ABS, a measure of adenosine burden. Data was also presented showing ABS outperformed other published adenosine signatures in specificity and sensitivity for detecting adenosine-rich microenvironments. Additionally, the research identified an inverse relationship between ABS and another published signature that has been shown to be predictive of anti-PD-1 therapy success, the Tumour Inflammation Score TIS .